Literature DB >> 27134854

Correlation of Paraoxonase Status with Disease Activity Score and Systemic Inflammation in Rheumatoid Arthritic Patients.

Usha Dudeja Bindal1, Rahul Saxena2, Merajul Haque Siddiqui3, Dilutpal Sharma4.   

Abstract

INTRODUCTION: Despite, various preventive efforts on conventional cardiovascular disease (CVD) risk factors, the incidence of CVD in rheumatoid arthritis (RA) patients increases continuously. To solve this conundrum one needs more investigations. AIM: The present study was conducted to evaluate the plasma paraoxonase (PON) activity along with the markers of systemic inflammation, oxidative stress and disease activity score-28 (DAS28) in RA patients and clarify their role in determining the probability of RA patients to develop future CVD risk.
MATERIALS AND METHODS: Plasma PON, total antioxidant activity (TAA), C-reactive protein (CRP), synovial interleukin-6 (IL-6) and erythrocyte malondialdehyde (MDA) levels were estimated in 40 RA patients aged 40-55 years aged and 40 age-matched healthy controls. The data obtained were compared statistically by using Student's t-test and Pearson correlation test.
RESULTS: Besides dyslipidaemia, marked reduction in plasma PON and TAA (p< 0.05) were observed in RA patients as compared with that of healthy controls. Erythrocyte MDA, plasma CRP and synovial IL-6 levels were increased significantly (p<0.05) in RA patients. PON was negatively correlated with MDA (r = - 0.672; p < 0.001), CRP (r = -0.458; p<0.05), IL-6 (r = -0.426; p<0.05) and DAS28 (r = -0.598; p < 0.001), and positively correlated with HDL cholesterol (r = 0.648; p<0.001) and TAA (r = 0.608; p< 0.001) levels in RA patients.
CONCLUSION: Alteration in PON activity might contribute to the progression of future CVD risk in RA patients, which may result from interplay of several confounding factors, such as inflammation, oxidative stress and dyslipidaemia. Furthermore, plasma PON activity, CRP and TAA levels could be considered as non-traditional factors to predict CVD risk. Thus, it is suggested that future drugs could be developed to target the non-traditional risk factors in RA patients.

Entities:  

Keywords:  C-reactive protein; Interleukin-6; Malondialdehyde; Total antioxidant activity

Year:  2016        PMID: 27134854      PMCID: PMC4843240          DOI: 10.7860/JCDR/2016/17767.7345

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  28 in total

1.  Method for the measurement of antioxidant activity in human fluids.

Authors:  D Koracevic; G Koracevic; V Djordjevic; S Andrejevic; V Cosic
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

2.  Lipid profiles in untreated patients with rheumatoid arthritis.

Authors:  Y B Park; S K Lee; W K Lee; C H Suh; C W Lee; C H Lee; C H Song; J Lee
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

5.  Efficacy of vitamin E in knee osteoarthritis management of North Indian geriatric population.

Authors:  Ijen Bhattacharya; Rahul Saxena; Veena Gupta
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-02       Impact factor: 5.346

Review 6.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

7.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

8.  Serum lipid profile paraoxonase and arylesterase activities in psoriasis.

Authors:  Aysun Toker; Melek Kadi; A Kadir Yildirim; Hulya Aksoy; Fatih Akçay
Journal:  Cell Biochem Funct       Date:  2009-04       Impact factor: 3.685

9.  Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.

Authors:  Frederick Wolfe; Bruce Freundlich; Walter L Straus
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

Review 10.  Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Authors:  Ernest Choy; Kandeepan Ganeshalingam; Anne Grete Semb; Zoltán Szekanecz; Michael Nurmohamed
Journal:  Rheumatology (Oxford)       Date:  2014-06-06       Impact factor: 7.580

View more
  2 in total

1.  Abnormal paraoxonase-1 (PON1) enzyme activity in idiopathic inflammatory myopathies.

Authors:  Sangmee Sharon Bae; Ani Shahbazian; Jennifer Wang; Ilana Golub; Buzand Oganesian; Tyler Dowd; Beata Vayngortin; Ryan Wang; David Elashoff; Srinivasa T Reddy; Christina Charles-Schoeman
Journal:  Rheumatology (Oxford)       Date:  2022-05-30       Impact factor: 7.046

2.  Evaluation of CYP1B1 Expression, Oxidative Stress and Phase 2 Detoxification Enzyme Status in Oral Squamous Cell Carcinoma Patients.

Authors:  Shailza Verma; Rahul Saxena; Merajul Haque Siddiqui; Karunathy Santha; Subramaniam Sethupathy
Journal:  J Clin Diagn Res       Date:  2017-03-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.